|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Shiraz University of Medical Sciences |
|---|---|
| Information provided by: | Shiraz University of Medical Sciences |
| ClinicalTrials.gov Identifier: | NCT00556465 |
Purpose
Diabetic nephropathy has become the single most frequent cause of end-stage renal disease.
On a molecular level, at least five major pathways have been implicated in glucose-mediated vascular and renal damage and all of these could reflect a single hyperglycaemia-induced process of overproduction of reactive oxygen species.
Recent studies have shown that inflammation, and more specifically pro-inflammatory cytokines play a determinant role in the development of micro- vascular diabetic complications, most of the attention has been focused on the implications of TNF-α in the setting of diabetic nephropathy.
Glutathione is the most abundant low-molecular-weight thiol, and Glutathione/ glutathione disulfide is the major redox couple in animal cells.
N-acetylcysteine is effective precursors of cysteine for tissue Glutathione synthesis.
Not only does N-acetylcysteine exhibit antioxidant properties, but it may also counteract the glycation cascade through the inhibition of oxidation.
N-acetylcysteine can also reduce the apoptosis elicited by reactive oxygen species .
Indeed, N-acetylcysteine has been shown to inhibit reactive oxygen species induced mesangial apoptosis and to be able to protect cells from glucose-induced inhibition of proliferation.
| Condition | Intervention | Phase |
|---|---|---|
|
Diabetic Nephropathy Chronic Kidney Disease Diabetes Type 2 |
Drug: N-acetylcysteine |
Phase II Phase III |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Study of N-Acetylcysteine for Treatment of Overt Diabetic Nephropathy |
| Enrollment: | 60 |
| Study Start Date: | January 2007 |
| Study Completion Date: | June 2007 |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: A, 1,III
in this arm patients took 1200 mg N-acetylcysteine
|
Drug: N-acetylcysteine
600 mg of effervescent N-acetylcysteine tablet twice per day for three months
|
| No Intervention: B,2, III |
Eligibility| Ages Eligible for Study: | 30 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Iran, Islamic Republic of | |
| Mohammad mahdi sagheb | |
| Shiraz, Fars, Iran, Islamic Republic of, 0098711 | |
| Study Director: | mohammad mahdi sagheb, MD | shiraz university of medical science |
More Information
| ClinicalTrials.gov Identifier: | NCT00556465 History of Changes |
| Other Study ID Numbers: | 3046 |
| Study First Received: | November 9, 2007 |
| Last Updated: | November 9, 2007 |
| Health Authority: | Iran: Ministry of Health |
|
diabetic nephropathy proteinuria antioxidant |
|
Diabetes Mellitus, Type 2 Diabetic Nephropathies Kidney Diseases Kidney Failure, Chronic Renal Insufficiency, Chronic Diabetes Mellitus Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Urologic Diseases Diabetes Complications Renal Insufficiency Acetylcysteine |
N-monoacetylcystine Antiviral Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Expectorants Respiratory System Agents Free Radical Scavengers Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs Antidotes |